Hyderabad, October 23, 2025: Laurus Labs Ltd., one of India’s leading pharmaceutical and biotech innovators, has delivered an impressive performance in the second quarter of FY26. The company’s net profit skyrocketed by 875% year-on-year, touching ₹195 crore, while revenues jumped 35% to ₹1,653 crore.
That’s a huge leap from ₹1,224 crore last year, showing how Laurus Labs’ R&D-driven strategy and expanding CDMO (Contract Development and Manufacturing Organization) business are paying off in a big way.
Strong Growth Across Segments
The company’s success this quarter comes from robust performance in both the CDMO and generics businesses. The CDMO division — which handles research, development, and manufacturing for global pharma partners — continues to drive sustainable revenue streams.
The EBITDA stood at ₹429 crore, a massive 136% increase compared to the same quarter last year, with margins improving to 26% from 14.9%. Gross margins also improved by nearly 5 percentage points to 59.9%, reflecting a stronger product mix and operational efficiencies.
Leadership Speaks: Confidence in Long-Term Growth
Dr. Satyanarayana Chava, Founder and CEO of Laurus Labs, said the company is maintaining its leadership position in antiretrovirals (ARVs) and is making progress in new clinical and commercial programs.
He highlighted Laurus Labs’ recent strategic moves, including:
- Investment of US$ 2 million in Aarvik Therapeutics to gain access to cutting-edge Antibody-Drug Conjugates (ADC) technology.
- Land allocation from the Andhra Pradesh government for expanding manufacturing capabilities.
Dr. Chava added that these initiatives will strengthen Laurus Labs’ integrated ADC services and boost its long-term growth potential.
CFO’s Take: Healthy Margins and Strong Fundamentals
V.V. Ravi Kumar, Executive Director and CFO, emphasized that Laurus Labs’ fundamentals remain solid, backed by steady growth in core businesses. He noted that EBITDA margins remain strong at 26%, supported by operational leverage.
For the first half (H1) of FY26, Laurus Labs reported:
- Revenue: ₹3,223 crore (up 33%)
- EBITDA: ₹818 crore (up 132%)
- Net Profit: ₹358 crore (up 985%)
- EPS: ₹6.6 compared to ₹0.6 last year
The company also managed to reduce net debt leverage to 1.3x EBITDA, even with ongoing CAPEX investments — a sign of healthy financial discipline.
Looking Ahead
Laurus Labs plans to continue investing in high-value CDMO and CMO opportunities to sustain its growth trajectory. With innovation at its core and expanding R&D capabilities, the company is well-positioned to capture both domestic and global market opportunities in pharma and biotech.
In short: Laurus Labs’ Q2 FY26 results showcase the power of innovation, strategic investments, and solid execution — proving why it’s one of India’s most exciting pharma success stories to watch.
Leave a Reply